JP2002531521A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2002531521A5 JP2002531521A5 JP2000586360A JP2000586360A JP2002531521A5 JP 2002531521 A5 JP2002531521 A5 JP 2002531521A5 JP 2000586360 A JP2000586360 A JP 2000586360A JP 2000586360 A JP2000586360 A JP 2000586360A JP 2002531521 A5 JP2002531521 A5 JP 2002531521A5
- Authority
- JP
- Japan
- Prior art keywords
- cell lines
- derived
- immunotherapeutic agent
- prostate cancer
- prostate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000002955 immunomodulating agent Substances 0.000 description 17
- 210000004027 cell Anatomy 0.000 description 16
- 206010060862 Prostate cancer Diseases 0.000 description 10
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 10
- 239000000203 mixture Substances 0.000 description 10
- 208000023958 prostate neoplasm Diseases 0.000 description 8
- 210000004881 tumor cell Anatomy 0.000 description 8
- 238000009169 immunotherapy Methods 0.000 description 7
- 230000001394 metastastic effect Effects 0.000 description 7
- 206010061289 metastatic neoplasm Diseases 0.000 description 7
- 238000000034 method Methods 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- 206010028980 Neoplasm Diseases 0.000 description 4
- 239000002671 adjuvant Substances 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 230000001024 immunotherapeutic effect Effects 0.000 description 3
- 210000002307 prostate Anatomy 0.000 description 3
- 239000008150 cryoprotective solution Substances 0.000 description 2
- 102000054766 genetic haplotypes Human genes 0.000 description 2
- 230000002163 immunogen Effects 0.000 description 2
- 210000005267 prostate cell Anatomy 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 239000012646 vaccine adjuvant Substances 0.000 description 2
- 229940124931 vaccine adjuvant Drugs 0.000 description 2
- 241000588832 Bordetella pertussis Species 0.000 description 1
- 102000016607 Diphtheria Toxin Human genes 0.000 description 1
- 108010053187 Diphtheria Toxin Proteins 0.000 description 1
- 102000008100 Human Serum Albumin Human genes 0.000 description 1
- 108091006905 Human Serum Albumin Proteins 0.000 description 1
- 102000013462 Interleukin-12 Human genes 0.000 description 1
- 108010065805 Interleukin-12 Proteins 0.000 description 1
- 102000000588 Interleukin-2 Human genes 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 102000004388 Interleukin-4 Human genes 0.000 description 1
- 108090000978 Interleukin-4 Proteins 0.000 description 1
- 102000000704 Interleukin-7 Human genes 0.000 description 1
- 108010002586 Interleukin-7 Proteins 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 108010055044 Tetanus Toxin Proteins 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 229940117681 interleukin-12 Drugs 0.000 description 1
- 229940028885 interleukin-4 Drugs 0.000 description 1
- 229940100994 interleukin-7 Drugs 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 229940118376 tetanus toxin Drugs 0.000 description 1
- 241001446247 uncultured actinomycete Species 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB9827103.4 | 1998-12-10 | ||
| GBGB9827103.4A GB9827103D0 (en) | 1998-12-10 | 1998-12-10 | New cancer treatments |
| PCT/GB1999/004135 WO2000033870A2 (en) | 1998-12-10 | 1999-12-09 | New cancer treatments |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2002531521A JP2002531521A (ja) | 2002-09-24 |
| JP2002531521A5 true JP2002531521A5 (https=) | 2007-01-11 |
| JP4607330B2 JP4607330B2 (ja) | 2011-01-05 |
Family
ID=10843925
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000586360A Expired - Fee Related JP4607330B2 (ja) | 1998-12-10 | 1999-12-09 | ガンの新規処置 |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US6699483B1 (https=) |
| EP (1) | EP1137434B1 (https=) |
| JP (1) | JP4607330B2 (https=) |
| KR (1) | KR100612552B1 (https=) |
| AT (1) | ATE412425T1 (https=) |
| AU (1) | AU777969B2 (https=) |
| CA (1) | CA2354046C (https=) |
| CZ (1) | CZ20012033A3 (https=) |
| DE (1) | DE69939837D1 (https=) |
| ES (1) | ES2315024T3 (https=) |
| GB (1) | GB9827103D0 (https=) |
| HU (1) | HUP0104857A3 (https=) |
| IL (2) | IL143295A0 (https=) |
| MX (1) | MXPA01005815A (https=) |
| NO (1) | NO326035B1 (https=) |
| NZ (1) | NZ512005A (https=) |
| PL (1) | PL348829A1 (https=) |
| WO (1) | WO2000033870A2 (https=) |
| ZA (1) | ZA200104163B (https=) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE60144515D1 (de) * | 2000-04-01 | 2011-06-09 | Onyvax Ltd | Prostata zellinien und deren verwendung |
| AU2002232560A1 (en) | 2000-10-27 | 2002-05-06 | Immuno-Rx, Inc | Vaccine immunotherapy for immune suppressed patients |
| US20070025958A1 (en) | 2000-10-27 | 2007-02-01 | Hadden John W | Vaccine immunotherapy |
| CA2476999C (en) * | 2002-02-22 | 2015-09-15 | Intracel Resources Llc | Sterile immunogenic non-tumorigenic tumor cell compositions and methods |
| US7176022B2 (en) * | 2002-12-20 | 2007-02-13 | Cell Genesys, Inc. | Directly injectable formulations which provide enhanced cryoprotection of cell products |
| US20050019336A1 (en) | 2003-07-23 | 2005-01-27 | Dalgleish Angus George | Human prostate cell lines in cancer treatment |
| US20050180952A1 (en) * | 2003-08-26 | 2005-08-18 | Pettis Ronald J. | Methods for intradermal delivery of therapeutics agents |
| EP2591786B1 (en) | 2003-10-16 | 2017-04-12 | Cancure Limited | Immunomodulating compositions and uses therefor |
| US8257715B1 (en) * | 2004-08-26 | 2012-09-04 | University Of Notre Dame | Tissue vaccines and uses thereof |
| US20090196850A1 (en) | 2005-01-06 | 2009-08-06 | Novo Nordisk A/S | Anti-Kir Combination Treatments and Methods |
| US9308252B2 (en) * | 2005-10-27 | 2016-04-12 | Cook Biotech, Inc. | Extracellular matrix materials as vaccine adjuvants for diseases associated with infectious pathogens or toxins |
| US8802113B2 (en) * | 2005-10-27 | 2014-08-12 | University Of Notre Dame | Extracellular matrix cancer vaccine adjuvant |
| US8778362B2 (en) | 2005-10-27 | 2014-07-15 | University Of Notre Dame | Anti-tumor/cancer heterologous acellular collagenous preparations and uses thereof |
| US8778360B2 (en) * | 2005-10-27 | 2014-07-15 | University Of Notre Dame | Extracellular matrix cancer vaccine adjuvant |
| GB0601598D0 (en) * | 2006-01-26 | 2006-03-08 | Stathopoulos Apostolos | Method |
| US9283266B2 (en) * | 2008-02-28 | 2016-03-15 | University Of Notre Dame | Metastasis inhibition preparations and methods |
| US20110250218A1 (en) | 2008-10-29 | 2011-10-13 | Fong Lawrence H | Disease-Associated Antigens and Methods of Use Thereof |
| CA3017298C (en) | 2009-05-15 | 2021-09-28 | Irx Therapeutics, Inc. | Compositions comprising primary cell-derived biologics for enhancing immune responses in patients |
| US8846059B2 (en) | 2009-12-08 | 2014-09-30 | University Of Notre Dame | Extracellular matrix adjuvant and methods for prevention and/or inhibition of ovarian tumors and ovarian cancer |
| ES2667476T3 (es) | 2009-12-08 | 2018-05-11 | Irx Therapeutics, Inc. | Método para invertir la supresión inmunitaria de células de Langerhans |
| US20110150934A1 (en) * | 2009-12-18 | 2011-06-23 | University Of Notre Dame | Ovarian Tumor Tissue Cell Preparations/Vaccines for the Treatment/Inhibition of Ovarian Tumors and Ovarian Cancer |
| CN105850982B (zh) * | 2016-04-29 | 2018-08-17 | 绍兴市人民医院 | 一种新型组织冻存液 |
| CN105850981B (zh) * | 2016-04-29 | 2018-07-20 | 绍兴市人民医院 | 冻存肿瘤组织的方法 |
| CN114729324A (zh) * | 2019-07-24 | 2022-07-08 | 斯比根公司 | 永生化干细胞株的制备方法及其用途 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5788963A (en) * | 1995-07-31 | 1998-08-04 | Pacific Northwest Cancer Foundation | Isolation and/or preservation of dendritic cells for prostate cancer immunotherapy |
| JP2000502711A (ja) * | 1995-12-28 | 2000-03-07 | ザ ジョンズ ホプキンズ ユニヴァーシティ スクール オブ メディシン | 同種異系パラクリンサイトカイン腫瘍ワクチン |
| WO1997028255A1 (en) * | 1996-02-02 | 1997-08-07 | The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Immortal human prostate epithelial cell lines and clones and their applications in the research and therapy of prostate cancer |
| EP1125133A1 (en) * | 1998-11-03 | 2001-08-22 | Cell Genesys, Inc. | Novel cancer-associated antigens and methods of their identification |
| GB9827104D0 (en) * | 1998-12-10 | 1999-02-03 | Onyvax Ltd | New cancer treatments |
-
1998
- 1998-12-10 GB GBGB9827103.4A patent/GB9827103D0/en not_active Ceased
-
1999
- 1999-12-09 NZ NZ512005A patent/NZ512005A/xx unknown
- 1999-12-09 AU AU16687/00A patent/AU777969B2/en not_active Ceased
- 1999-12-09 JP JP2000586360A patent/JP4607330B2/ja not_active Expired - Fee Related
- 1999-12-09 AT AT99959548T patent/ATE412425T1/de not_active IP Right Cessation
- 1999-12-09 CZ CZ20012033A patent/CZ20012033A3/cs unknown
- 1999-12-09 KR KR1020017007095A patent/KR100612552B1/ko not_active Expired - Fee Related
- 1999-12-09 HU HU0104857A patent/HUP0104857A3/hu unknown
- 1999-12-09 US US09/857,690 patent/US6699483B1/en not_active Expired - Lifetime
- 1999-12-09 EP EP99959548A patent/EP1137434B1/en not_active Expired - Lifetime
- 1999-12-09 ES ES99959548T patent/ES2315024T3/es not_active Expired - Lifetime
- 1999-12-09 WO PCT/GB1999/004135 patent/WO2000033870A2/en not_active Ceased
- 1999-12-09 CA CA2354046A patent/CA2354046C/en not_active Expired - Fee Related
- 1999-12-09 MX MXPA01005815A patent/MXPA01005815A/es active IP Right Grant
- 1999-12-09 DE DE69939837T patent/DE69939837D1/de not_active Expired - Lifetime
- 1999-12-09 IL IL14329599A patent/IL143295A0/xx active IP Right Grant
- 1999-12-09 PL PL99348829A patent/PL348829A1/xx unknown
-
2001
- 2001-05-22 IL IL143295A patent/IL143295A/en not_active IP Right Cessation
- 2001-05-22 ZA ZA200104163A patent/ZA200104163B/en unknown
- 2001-06-07 NO NO20012818A patent/NO326035B1/no not_active IP Right Cessation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2002531521A5 (https=) | ||
| CA2354046A1 (en) | New cancer treatments | |
| TWI232753B (en) | Adjuvant compositions comprising QS-21,3D-MPL and CpG and vaccine compositions comprising the same | |
| JP2012021028A5 (https=) | ||
| ES2257769T3 (es) | Metodo para la preparacion de vacunas multivalentes. | |
| JP2006506441A5 (https=) | ||
| HU229968B1 (hu) | Sztreptokokkusz oltóanyag | |
| JP2010505850A5 (https=) | ||
| HU228384B1 (en) | Vaccine compositions | |
| HUP9901254A2 (hu) | Nemdendrites szerkezetű gerincet alkotó peptid hordozó | |
| Xiang et al. | Promising particle-based vaccines in cancer therapy | |
| JP2003513935A5 (https=) | ||
| JP2002531520A5 (https=) | ||
| WO2001035989A3 (de) | Verwendung von anti-idiotypische antikörpern als impfstoffe gegenkrebs | |
| Baker et al. | BCG in malignant melanoma | |
| WO2005084387A3 (en) | Methods and compositions for hybrid cell vaccines for the treatment and prevention of cancer | |
| MY127452A (en) | Vaccines. | |
| Suntharalingam et al. | The use of concurrent chemotherapy with high-dose radiation before surgical resection in patients presenting with apical sulcus tumors. | |
| ES2241122T3 (es) | Formulaciones de inmunopotenciacion para uso como vacunas. | |
| WO2002080981A3 (en) | Polynucleotide binding complexes comprising sterols and saponins | |
| JP5186678B2 (ja) | 経皮抗原投与のための抗原キット | |
| WO2002030458A8 (en) | Yersinia adhesion protein as vaccine adjuvant | |
| AU2004216554B2 (en) | Subcutaneously-administered ganglioside-based vaccine compositions | |
| Hoover et al. | Tumor-specific BCG therapy in colon cancer | |
| Lasalvia-Prisco et al. | 804 POSTER Conditioning of vaccine sentinel lymph node as adjuvant of autologous hemoderivative breast cancer vaccine |